Eterna Therapeutics (ERNA) Stock Highlights

0.98 | -6.67%

2024-10-02 06:15:59

Eterna Therapeutics Inc, formerly Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

Statistics

Range Today

0.96 1.18

Volume Today 17.6K

Range 1 Year

0.84 2.63

Volume 1 Year 4.73M

Range 3 Year

0.84 202

Volume 3 Year 23.24M

Range 10 Year

0.84 1613.4

Volume 10 Year 64.83M

Highlights

Market Capitalization 6.87M (micro)

Floating Shares 2.96M

Current Price 0.98

Price To Earnings -0.27

Price To Revenue 326.19

Earnings Per Share -4.43

Payout Ratio 0%

Performance

Latest -6.67%

1 Month -44.94%

3 Months -44.32%

6 Months -60.32%

1 Year -53.99%

3 Years -99.47%

5 Years -99.28%

10 Years -99.87%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.